You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

The importance of haptenprotein complex formation in the development of drug allergy

Faulkner, Lee; Meng, Xiaoli; Park, B. Kevin; Naisbitt, Dean J.

Current Opinion in Allergy & Clinical Immunology:
doi: 10.1097/ACI.0000000000000078
DRUG ALLERGY: Edited by Bernard Y. Thong and Miguel Blanca
Abstract

Purpose of review: Drug allergy is an adverse drug reaction that is immune-mediated. Immune activation can occur when drugs or haptens bind covalently to proteins and then act as antigens. The purpose of this review is to summarize the recent data on the formation of hapten–protein complexes and to assess the importance of these complexes in the generation of drug allergy.

Recent findings: The formation of hapten–protein complexes by drugs and their reactive metabolites has largely been investigated using model proteins such as human serum albumin. Precise identification of the structure of the hapten and the resulting modified residue(s) in the protein has been undertaken for a small number of drugs, such as p-phenylenediamine, nevirapine, carbamazepine, β-lactams and abacavir. Some progress has also been made in identifying hapten–protein complexes in the serum of patients with allergy.

Summary: Drug-specific T cells have been isolated from different patients with allergy. Formation of hapten–protein complexes, their processing and antigen presentation have been implicated in the development of drug allergy to p-phenylenediamine, sulfonamides and β-lactams. However, evidence also supports the pi mechanism of immune activation wherein drugs interact directly with immune receptors. Thus, multiple mechanisms of immune activation may occur for the same drug.

Author Information

MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Correspondence to Dean J. Naisbitt, MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Ashton Street, Liverpool, L69 3GE, UK. Tel: +44 151 794 5346; fax: +44 151 794 4450; e-mail: dnes@liv.ac.uk, d.j.naisbitt@liverpool.ac.uk

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.